Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn’s disease.

Current stock price: 67.90 pence, up 1.3% on Monday

12-month change: up 10%

Copyright 2022 Alliance News Limited. All Rights Reserved.